Issues related to regulatory and legislative developments regarding biosimilars and prescription digital therapeutics.
2025 · 3rd Quarter (July 1 - Sep 30)
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Filed by ALB SOLUTIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- ALB SOLUTIONS
- Filing UUID
- 8b7f0824-353e-4419-9e8b-9d601c536852
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.